ARTELO BIOSCIENCES, INC.

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling pathways. The company's product pipeline centers on three primary candidates: ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist currently in Phase 1b/2a trials for cancer-related anorexia; ART12.11, a cocrystal composition combining cannabidiol and tetramethylpyrazine being evaluated for anxiety, depression, post-traumatic stress disorder, epilepsy, and insomnia; and ART26.12, a fatty acid binding protein 5 inhibitor under development for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, pain conditions, and various cancers.

The company operates at an early stage with seven full-time employees and is headquartered in Solana Beach, California. As a clinical-stage entity, Artelo does not generate product revenues. The company was incorporated in Nevada in 2011, originally under the name Reactive Medical Inc., and adopted its current name in April 2017.